Literature DB >> 10534173

Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements.

M Emoto1, H Iwasaki, M Ishiguro, M Kikuchi, S Horiuchi, T Saito, N Tsukamoto, T Kawarabayashi.   

Abstract

Carcinosarcoma of the uterus is a highly aggressive neoplasm. However, the angiogenesis of this neoplasm is still unknown. This is the first study to examine the differences in angiogenesis between the epithelial and mesenchymal elements of this biphasic neoplasm. Surgical specimens from 21 primary uterine carcinosarcomas were histopathologically evaluated, and then immunohistochemically analyzed for tumor angiogenesis, using an anti-vascular endothelial growth factor (VEGF) antibody. The microvessel density (MVD) was also measured in each element of these neoplasms, using anti-CD34 monoclonal antibody. The MVD in the epithelial element was found to be higher than that of the mesenchymal element in 20 of 21 (95.2%) primary tumors. The epithelial elements showed a higher MVD (mean, 81.6 +/- 41.1) than the mesenchymal elements (mean, 36.7 +/- 23.8) in these primary tumors (P < .0001). Moreover, the epithelial elements showed a higher VEGF expression (mean, 0.78 +/- 0.23) than the mesenchymal elements (mean, 0.37 +/- 0.20) (P < .0001). The tumors with lymph-vascular invasion showed a higher VEGF expression (n = 17; mean, 0.85 +/- 0.17) than the tumors without lymph-vascular invasion (n = 4, mean, 0.47 +/- 0.12) (P < .01). Microscopically, neither lymph-vascular space invasion nor metastatic tumors consisted of sarcoma alone in this series. In addition, a decrease in the VEGF expression was found in the transitional areas between carcinomatous and sarcomatous elements in all 10 homologous and 4 heterologous tumors evaluated. These results suggest that the tumor angiogenesis in the epithelial element may be more active than that of the mesenchymal element and also substantiated the high metastatic potential of the epithelial element in uterine carcinosarcoma. Based on these findings, carcinoma cells thus may play a key role in the angiogenesis of this biphasic neoplasm.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534173     DOI: 10.1016/s0046-8177(99)90043-6

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

Review 2.  Angiogenesis in epithelian ovarian cancer.

Authors:  E S Bamberger; C W Perrett
Journal:  Mol Pathol       Date:  2002-12

Review 3.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

4.  Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.

Authors:  Anil Potti; Apar Kishor Ganti; Ketki Tendulkar; Kaley Sholes; Sidharth Chitajallu; Michael Koch; Steven Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-05       Impact factor: 4.553

5.  Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.

Authors:  Alexander Schipf; Doris Mayr; Thomas Kirchner; Joachim Diebold
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

Review 6.  Development of a Cancer Treatment with the Concomitant Use of Low-Intensity Ultrasound: Entering the Age of Simultaneous Diagnosis and Treatment.

Authors:  Makoto Emoto
Journal:  Diagnostics (Basel)       Date:  2014-04-22

7.  Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies.

Authors:  Theresa L Schwartz; Harveshp Mogal; Christos Papageorgiou; Jula Veerapong; Eddy C Hsueh
Journal:  Exp Hematol Oncol       Date:  2013-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.